Merck shares rise after Barclays upgrades shares, downgrades competitor Pfizer

Barclays upgraded Merck to overweight from equal weight on better opportunities versus its competition, while downgrading Pfizer to equal weight from overweight given the less likely chance of a "transformative" acquisition.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.